## Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 4

Form 4	ARMACEUTI	CALS CO	RP							
May 26, 2005	Л							OMB A	PPROVAL	
FORM	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Statement OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Estimated burden hou response	Estimated average burden hours per response 0.5	
(Print or Type Re	sponses)									
1. Name and Add EVNIN LUK	2. Issuer Name and Ticker or Trading Symbol OSCIENT PHARMACEUTICALS CORP [OSCI]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	(Last) (First) (Middle)			3. Date of Earliest Transaction			X Director Officer (giv		% Owner her (specify	
1000 WINTE 2200	ITE	(Month/Day/Year) 05/25/2005			below)	below)	ici (specify			
				4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
WALTHAM, MA 02451 Form filed by More than One Report Person							eporung			
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	. Transaction Date Month/Day/Year)		Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Repor	rt on a separate line	for each cla	ass of sec	urities bene	eficially ow	ned directly	or indirectly.			
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.SEC 1474 (9-02)										
	Tab					posed of, or convertible	· Beneficially Owner securities)	d		

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5.	Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionD	erivative	Expiration Date	Underlying Securities	D

## Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(A) ed of	(Month/Day/Year) f		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	\$ 1.78	05/25/2005		А	12,000		<u>(1)</u>	05/24/2015	Common stock	12,000

## **Reporting Owners**

Reporting Owner Name / Address		Relationsh		
	Director	10% Owner	Officer	Other
EVNIN LUKE 1000 WINTER STREET SUITE 2200 WALTHAM, MA 02451	Х			
Signatures				
Robert E. Farrell Jr Corp Controller/Tre Attorney		05/26/2005		
<u>**</u> Signature of Reporting Pers		Date		

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Re-election to Board - vest annually in equal installments over 3 years from date of grant

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S ()